Alcon, Inc. Release: New RETAANE Clinical Study Data Reported At Macula Society Meeting

FORT WORTH, Texas--(BUSINESS WIRE)--Feb. 25, 2005--Alcon, Inc. (NYSE:ACL) reported the results of a clinical pharmacokinetic (PK) study evaluating the effectiveness of a counter pressure device (CPD) it developed to control reflux during the administration of RETAANE(R) 15mg (anecortave acetate for depot suspension) by posterior juxtascleral depot (PJD). The results of this PK study demonstrated that the CPD was effective in controlling drug reflux in 100 percent of the study participants. Reflux occurs when a portion of the drug leaks back out through the small incision in the conjunctiva during or immediately following the PJD procedure. Henry L. Hudson, M.D. of Tucson, Ariz., and Donald Roy, M.D. of Fresno, Calif., conducted the study. Allen C. Ho, M.D. of Philadelphia, presented the data at the 28th Annual Macula Society Meeting in Key Biscayne, Fla.